{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:46:08Z","timestamp":1770284768987,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,2,5]],"date-time":"2010-02-05T00:00:00Z","timestamp":1265328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/cdd.2010.6","type":"journal-article","created":{"date-parts":[[2010,2,5]],"date-time":"2010-02-05T15:44:15Z","timestamp":1265384655000},"page":"1211-1220","source":"Crossref","is-referenced-by-count":35,"title":["Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment"],"prefix":"10.1038","volume":"17","author":[{"given":"M","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kawatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Osada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Tsuruo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,5]]},"reference":[{"key":"BFcdd20106_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"key":"BFcdd20106_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV . Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451\u20131464.","journal-title":"N Engl J Med"},{"key":"BFcdd20106_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFcdd20106_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFcdd20106_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFcdd20106_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFcdd20106_CR7","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948\u20133954.","journal-title":"Blood"},{"key":"BFcdd20106_CR8","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","volume":"14","author":"J Kuroda","year":"2007","unstructured":"Kuroda J, Kimura S, Strasser A, Andreeff M, O\u2019Reilly LA, Ashihara E et al. Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Diff 2007; 14: 1667\u20131677.","journal-title":"Cell Death Diff"},{"key":"BFcdd20106_CR9","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/cdd.2008.107","volume":"15","author":"Y Kamitsuji","year":"2008","unstructured":"Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E et al. Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Diff 2008; 15: 1712\u20131722.","journal-title":"Cell Death Diff"},{"key":"BFcdd20106_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","volume":"8","author":"R Tanaka","year":"2008","unstructured":"Tanaka R, Kimura S . From the second generation Abl tyrosine kinase inhibitors to the next generation for overriding Bcr-Abl\/T315I. Exp Rev Anticancer Ther 2008; 8: 1387\u20131398.","journal-title":"Exp Rev Anticancer Ther"},{"key":"BFcdd20106_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267\u20131270.","journal-title":"Nature"},{"key":"BFcdd20106_CR12","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFcdd20106_CR13","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1073\/pnas.0701152104","volume":"104","author":"K Parmar","year":"2007","unstructured":"Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD . Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431\u20135436.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcdd20106_CR14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V82.7.2031.2031","volume":"82","author":"MG Cipolleschi","year":"1993","unstructured":"Cipolleschi MG, Dello Sbarba P, Olivotto M . The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993; 82: 2031\u20132037.","journal-title":"Blood"},{"key":"BFcdd20106_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1046\/j.1365-2184.2000.00183.x","volume":"33","author":"PO Jensen","year":"2000","unstructured":"Jensen PO, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, Helledie N et al. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukemia in rats. Cell Prolif 2000; 33: 381\u2013395.","journal-title":"Cell Prolif"},{"key":"BFcdd20106_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc2067","volume":"7","author":"A Albini","year":"2007","unstructured":"Albini A, Sporn MB . The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7: 139\u2013147.","journal-title":"Nat Rev Cancer"},{"key":"BFcdd20106_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.leu.2404432","volume":"21","author":"M Ninomiya","year":"2007","unstructured":"Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007; 21: 136\u2013142.","journal-title":"Leukemia"},{"key":"BFcdd20106_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0093-7754(01)90210-6","volume":"28","author":"P Vaupel","year":"2001","unstructured":"Vaupel P, Kelleher DK, Hockel M . Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28: 29\u201335.","journal-title":"Semin Oncol"},{"key":"BFcdd20106_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ . Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891\u2013899.","journal-title":"Nat Rev Cancer"},{"key":"BFcdd20106_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4161\/cbt.1.5.157","volume":"1","author":"JM Brown","year":"2002","unstructured":"Brown JM . Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1: 453\u2013458.","journal-title":"Cancer Biol Ther"},{"key":"BFcdd20106_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drup.2003.12.004","volume":"7","author":"BG Wouters","year":"2004","unstructured":"Wouters BG, van den Beucken T, Magagnin MG, Lambin P, Koumenis C . Targeting hypoxia tolerance in cancer. Drug Resist Updat 2004; 7: 25\u201340.","journal-title":"Drug Resist Updat"},{"key":"BFcdd20106_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J . The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311\u2013322.","journal-title":"J Cell Physiol"},{"key":"BFcdd20106_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nri1779","volume":"6","author":"A Wilson","year":"2006","unstructured":"Wilson A, Trumpp A . Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93\u2013106.","journal-title":"Nat Rev Immunol"},{"key":"BFcdd20106_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528\u2013541.","journal-title":"Cancer Cell"},{"key":"BFcdd20106_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1634\/stemcells.2007-0861","volume":"26","author":"B Moshaver","year":"2008","unstructured":"Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008; 26: 3059\u20133067.","journal-title":"Stem Cells"},{"key":"BFcdd20106_CR26","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood.V95.10.3214","volume":"95","author":"H Sakamoto","year":"2000","unstructured":"Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95: 3214\u20133218.","journal-title":"Blood"},{"key":"BFcdd20106_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.bmcl.2004.12.031","volume":"15","author":"D Kamiya","year":"2005","unstructured":"Kamiya D, Uchihata Y, Ichikawa E, Kato K, Umezawa K . Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. Bioorg Med Chem Lett 2005; 15: 1111\u20131114.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFcdd20106_CR28","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.1073\/pnas.0712239105","volume":"105","author":"M Kawatani","year":"2008","unstructured":"Kawatani M, Okumura H, Honda K, Kanoh N, Muroi M, Dohmae N et al. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc Natl Acad Sci USA 2008; 105: 11691\u201311696.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcdd20106_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","volume":"142","author":"P Valent","year":"2008","unstructured":"Valent P . Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haemato 2008; 142: 361\u2013378.","journal-title":"Br J Haemato"},{"key":"BFcdd20106_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1634\/stemcells.20-4-347","volume":"20","author":"V Desplat","year":"2002","unstructured":"Desplat V, Faucher JL, Mahon FX, Dello Sbarba P, Praloran V, Ivanovic Z . Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem Cells 2002; 20: 347\u2013354.","journal-title":"Stem Cells"},{"key":"BFcdd20106_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","volume":"20","author":"S Giuntoli","year":"2006","unstructured":"Giuntoli S, Rovida E, Barbetti V . Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006; 20: 1291\u20131293.","journal-title":"Leukemia"},{"key":"BFcdd20106_CR32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/stemcells.2006-0637","volume":"25","author":"S Giuntoli","year":"2007","unstructured":"Giuntoli S, Rovida E, Gozzini A . Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells. Stem Cells 2007; 25: 1119\u20131125.","journal-title":"Stem Cells"},{"key":"BFcdd20106_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189\u2013218.","journal-title":"Leukemia"},{"key":"BFcdd20106_CR34","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1101\/gad.889901","volume":"15","author":"K Gottlob","year":"2001","unstructured":"Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N . Inhibition of early apoptotic events by Akt\/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406\u20131418.","journal-title":"Genes Dev"},{"key":"BFcdd20106_CR35","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/MCB.01535-06","volume":"27","author":"JK Brunelle","year":"2007","unstructured":"Brunelle JK, Shroff EH, Perlman H . Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol 2007; 27: 1222\u20131235.","journal-title":"Mol Cell Biol"},{"key":"BFcdd20106_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O . On the origin of cancer cells. Science 1956; 123: 309\u2013314.","journal-title":"Science"},{"key":"BFcdd20106_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1128\/MCB.22.1.94-104.2002","volume":"22","author":"DS McClintock","year":"2002","unstructured":"McClintock DS, Santore MT, Lee VY, Brunelle J, Budinger GR, Zong WX et al. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol Cell Biol 2002; 22: 94\u2013104.","journal-title":"Mol Cell Biol"},{"key":"BFcdd20106_CR38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.613.65.2","volume":"65","author":"RH Xu","year":"2005","unstructured":"Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613\u2013621.","journal-title":"Cancer Res"},{"key":"BFcdd20106_CR39","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633\u20134646.","journal-title":"Oncogene"},{"key":"BFcdd20106_CR40","first-page":"2513","volume":"7","author":"H Sakamoto","year":"2001","unstructured":"Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T et al. Selective activation of apoptosis program by S-p-bromobenzyl glutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001; 7: 2513\u20132518.","journal-title":"Clin Cancer Res"},{"key":"BFcdd20106_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1172\/JCI23043","volume":"115","author":"M Nogawa","year":"2005","unstructured":"Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115: 978\u2013985.","journal-title":"J Clin Invest"},{"key":"BFcdd20106_CR42","first-page":"1379","volume":"55","author":"S Kimura","year":"1995","unstructured":"Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T . Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379\u20131384.","journal-title":"Cancer Res"},{"key":"BFcdd20106_CR43","doi-asserted-by":"crossref","unstructured":"Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K et al. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res 2009; (in press).","DOI":"10.1182\/blood.V114.22.4245.4245"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cdd20106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd20106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd20106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:46:29Z","timestamp":1685418389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cdd20106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,5]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["BFcdd20106"],"URL":"https:\/\/doi.org\/10.1038\/cdd.2010.6","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,5]]}}}